QUIDEL CORP Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 20 rows in 2014. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2014-11-17: Reporting owner WIDDER KENNETH J; Form 4; Security Non-Qualified Stock Option; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2014-11-04: Reporting owner Dammeyer Rodney F; Form 4; Security Non-Qual Stock Options; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2014-11-04: Reporting owner Dammeyer Rodney F; Form 4; Security Non-Qual Stock Options; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2014-10-03: Reporting owner TAMERIUS JOHN; Form 4; Security Non-Qualified Stock Option; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2014-11-17 | WIDDER KENNETH J Director | 4 | Non-Qualified Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,333 3,333 owned after | $27.91 exercise price | 2014-11-19 | |
| 2014-11-04 | Dammeyer Rodney F Director | 4 | Non-Qual Stock Options Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,331 0 owned after | $9.93 exercise price | 2014-11-06 | |
| 2014-11-04 | Dammeyer Rodney F Director | 4 | Non-Qual Stock Options Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,331 0 owned after | $13.97 exercise price | 2014-11-06 | |
| 2014-10-03 | TAMERIUS JOHN Officer (SVP - Clinical/Reg Affairs) | 4 | Non-Qualified Stock Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 36,401 owned after | $8.50 exercise price | 2014-10-09 | |
| 2014-09-18 | TAMERIUS JOHN Officer (SVP - Clinical/Reg Affairs) | 4 | Non-Qualified Stock Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 41,401 owned after | $8.50 exercise price | 2014-09-19 | |
| 2014-05-27 | Kroll Werner Officer (SVP, R&D) | 4 | Non-Qualified Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +26,483 26,483 owned after | $22.85 exercise price | 2014-05-29 | |
| 2014-05-06 | SCHULER JACK W Director, 10% Owner | 4 | Non-Qualified Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,041 9,041 owned after | $21.07 exercise price | 2014-11-18 | |
| 2014-05-06 | PULIDO MARK Director | 4 | Non-Qualified Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,866 11,866 owned after | $21.07 exercise price | 2014-11-12 | |
| 2014-05-06 | POLAN MARY LAKE PH D Director | 4 | Non-Qualified Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,041 9,041 owned after | $21.07 exercise price | 2014-11-12 | |
| 2014-05-06 | Dammeyer Rodney F Director | 4 | Non-Qualified Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,041 9,041 owned after | $21.07 exercise price | 2014-11-12 | |
| 2014-05-06 | BUECHLER KENNETH F Director | 4 | Non-Qualified Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,041 9,041 owned after | $21.07 exercise price | 2014-11-12 | |
| 2014-05-06 | Brown Thomas D Director | 4 | Non-Qualified Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,041 9,041 owned after | $21.07 exercise price | 2014-11-12 | |
| 2014-02-26 | TAMERIUS JOHN Officer (SVP - Clinical/Reg Affairs) | 4 | Non-Qualified Stock Options Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,891 16,109 owned after | $12.63 exercise price | 2014-02-26 | |
| 2014-02-26 | TAMERIUS JOHN Officer (SVP - Clinical/Reg Affairs) | 4 | Non-Qualified Stock Options Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,891 4,630 owned after | $15.28 exercise price | 2014-02-26 | |
| 2014-02-24 | TAMERIUS JOHN Officer (SVP - Clinical/Reg Affairs) | 4 | Non-Qualified Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +21,068 21,068 owned after | $27.57 exercise price | 2014-02-26 | |
| 2014-02-24 | STEWARD RANDALL J Officer (Chief Financial Officer) | 4 | Non-Qualified Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +38,162 38,162 owned after | $27.57 exercise price | 2014-02-26 | |
| 2014-02-24 | Stenzel Timothy Todd Officer (Chief Science Officer) | 4 | Non-Qualified Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,901 15,901 owned after | $27.57 exercise price | 2014-02-26 | |
| 2014-02-24 | SMITS MARK W Officer (SVP-Commercial Operations) | 4 | Non-Qualified Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +33,392 33,392 owned after | $27.57 exercise price | 2014-02-26 | |
| 2014-02-24 | Bujarski Robert Joseph Officer (SVP, Bus Dev & Gen Counsel) | 4 | Non-Qualified Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +28,621 28,621 owned after | $27.57 exercise price | 2014-02-26 | |
| 2014-02-24 | BRYANT DOUGLAS C Director, Officer (President & CEO) | 4 | Non-Qualified Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +93,021 93,021 owned after | $27.57 exercise price | 2014-02-26 |